Add 2 More Reports For 20% off

Report Overview

The RNA therapeutics market was valued at USD 13.70 Billion in 2023, driven by the increasing FDA approvals for RNAi-based therapies across the globe. The market is anticipated to grow at a CAGR of 5.60% during the forecast period of 2024-2032, with the values likely to reach USD 22.37 Billion by 2032.

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

  • The market is poised for rapid growth driven by advancements in mRNA technology, particularly for vaccine development and gene silencing therapies, addressing a broad range of diseases with high precision and effectiveness.
  • Increasing investments in RNA-based drug research, coupled with growing FDA approvals for innovative therapies, are expanding the market's scope, offering novel treatment options for rare genetic disorders and complex diseases like cancer and cardiovascular conditions.
  • The rise of personalised medicine and RNA's ability to target specific genetic pathways are fostering demand, positioning RNA therapeutics as a transformative solution in healthcare, significantly boosting market expansion during the forecast period.

RNA Therapeutics Market Overview

RNA therapeutics involve using RNA molecules to treat diseases by targeting gene expression at the RNA level. Key approaches include mRNA therapies, which instruct cells to produce therapeutic proteins, RNA interference (RNAi) to silence harmful genes, and antisense oligonucleotides (ASOs) to modify RNA splicing or stability. These therapies have significant potential for treating genetic disorders, cancers, and viral infections. By directly targeting the root causes of diseases at a molecular level, RNA therapeutics offer a promising and innovative approach to medicine.

RNA Therapeutics Market Growth Drivers

Surge in FDA Approvals to Boost Market Value

The increasing prevalence of cancer and advancements in RNA-targeting technologies are significant drivers of market growth. In July 2024, Rgenta Therapeutics received FDA clearance for its Investigational New Drug (IND) application for RGT-61159, an innovative oral small molecule targeting RNA regulation. The drug is designed for the treatment of adenoid cystic carcinoma, colorectal cancer, solid tumors, and acute myeloid leukemia. This milestone highlights the shift toward RNA-based therapies in oncology. The approval is poised to accelerate investments in RNA-targeting drugs and expand the pipeline of RNA-based oncology treatments, boosting market value in the forecast period.

Rising Preference for Precision Medicine to Boost RNA Therapeutics Market Demand

Rising demand for precision medicine and breakthroughs in RNA-editing technologies drive market expansion. In November 2024, HuidaGene Therapeutics achieved FDA clearance for HG202, the first-ever CRISPR/Cas13 RNA-editing therapy designed for clinical use. This innovative treatment targets neovascular age-related macular degeneration, a leading cause of blindness. The development of HG202 underscores the growing potential of RNA-editing platforms. This approval is expected to foster competition, encourage global collaborations, and solidify RNA-editing’s role in addressing unmet medical needs, further enhancing the market’s growth trajectory during the forecast period.

RNA Therapeutics Market Trends

RNA Therapeutics Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Product

  • Vaccines
  • Drugs

Market Breakup by Type

  • mRNA Therapeutics
  • RNA Interference (RNAi) Therapeutics
  • Antisense Oligonucleotide (ASO) Therapeutics
  • Others

Market Breakup by Indication

  • Infective Diseases
  • Rare Genetic Diseases/Hereditary Diseases
  • Others

Market Breakup by End User

  • Hospitals and Clinics
  • Research Settings
  • Others

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

RNA Therapeutics Market Share

Market Segmentation by Type to Witness Growth

The market share by type constitutes mRNA therapeutics, RNA interference (RNAi) therapeutics, antisense oligonucleotide (ASO) therapeutics and others. The mRNA therapeutics segment dominates the RNA therapeutics market by type, driven by the success of mRNA-based vaccines like those for COVID-19. Its rapid adaptability to emerging diseases and scalability in production gives it an edge.

RNA Therapeutics Market Analysis by Region

North America leads the market share due to its advanced healthcare infrastructure, strong presence of biotechnology companies, and significant investments in R&D. The region benefits from a high prevalence of target diseases, robust regulatory frameworks, and government funding supporting RNA-based drug development. Additionally, North America hosts leading players pioneering RNA technology, including mRNA vaccines and gene silencing therapies, driving rapid market growth. The early adoption of innovative therapies and strategic partnerships between academia and industry further strengthen its dominance. This competitive edge positions North America as the key driver of the market globally.

Leading Players in the RNA Therapeutics Market

The key features of the market report comprise patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Moderna, Inc.

Headquartered in Cambridge, Massachusetts, USA, Moderna was founded in 2010. The company is a pioneer in messenger RNA (mRNA) technology, having gained global recognition for its COVID-19 vaccine, Spikevax. Moderna is also advancing mRNA-based therapeutics across multiple disease areas, including oncology, rare genetic disorders, and infectious diseases. Its expanding portfolio focuses on developing mRNA medicines that deliver genetic instructions to cells, offering potential treatments for previously hard-to-address conditions.

BioNTech SE

BioNTech, based in Mainz, Germany, was established in 2008. The company is a leader in the development of mRNA...

Alnylam Pharmaceuticals, Inc.

Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is a leader in RNA inte...

Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, established in 1989 and headquartered in Carlsbad, California, specialises in antisense...

*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*

Other key players in the market include Arcturus Therapeutics Holdings Inc., CureVac N.V., Sarepta Therapeutics, Inc., Wave Life Sciences Ltd., Sanofi S.A., and Novo Nordisk A/S.

Key Questions Answered in the RNA Therapeutics Market

  • What was the RNA therapeutics market value in 2023?
  • What is the RNA therapeutics market forecast outlook for 2024-2032?
  • What is the market breakup based on the product?
  • What is the market breakup based on the type?
  • What is the market breakup based on the indication?
  • What is the market breakup based on the end user?
  • What are the major factors aiding the RNA therapeutics market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the market's major drivers, opportunities, and restraints?
  • Which country is expected to experience expedited growth during the forecast period?
  • What are the major RNA therapeutics market trends?
  • Which product will lead the market segment?
  • Which type will lead the market segment?
  • Which indication will lead the market segment?
  • Which end user will lead the market segment?
  • Who are the key players involved in the RNA therapeutics market?
  • What is the patent landscape of the market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Type
  • Indication
  • End User
  • Region
Breakup by Product
  • Vaccines
  • Drugs
Breakup by Type
  • mRNA Therapeutics
  • RNA Interference (RNAi) Therapeutics
  • Antisense Oligonucleotide (ASO) Therapeutics
  • Others
Breakup by Indication
  • Infective Diseases
  • Rare Genetic Diseases/Hereditary Diseases
  • Others
Breakup by End User
  • Hospitals & Clinics
  • Research Center
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • PESTEL Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Company News and Developments
    • Certifications
Companies Covered
  • Moderna, Inc.
  • BioNTech SE
  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Arcturus Therapeutics Holdings Inc.
  • CureVac N.V.
  • Sarepta Therapeutics, Inc.
  • Wave Life Sciences Ltd.
  • Novo Nordisk A/S
  • Sanofi S.A.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124